Live
FierceBiotechTransforming neurodegenerative disease treatmentFierceBiotechAdvances and Opportunities in Dual Chamber InjectablesFierceBiotechAchieving Effective Manufacturing Scaleup for Clinical and Commercial SuccessFierceBiotechUtilizing AI to Facilitate Combination Product DevelopmentFierceBiotechEnsuring Sustainability Throughout Drug and Device DevelopmentFierceBiotechUsing Digital Technologies to Enhance Patient Experience and Better Manage Supply ChainEndpoints NewsCDER chief Høeg expected to leave FDA, according to sourceClinical OMICsPPG-Derived Digital Biomarker Developed for Peripheral Artery Disease DetectionCharles RiverCharles River Laboratories stock (US1591881009): recent earnings and outlook under the microscope - AD HOC NEWSClinical OMICsAntibody-Drug Conjugate Shows Activity in Hard-to-Treat Uterine CancerClinical OMICsExchange Marketplace Launched to Help Stalled Cell and Gene TherapiesClinical OMICsSingle Psilocybin Dose Relieves Depression for Over Three Months
Endpoints News Mar 31, 2026

AstraZeneca's next-gen hopeful for a rare bone condition fails pivotal trial

AstraZeneca's next-gen hopeful for a rare bone condition fails pivotal trial

Original
Body unavailable. Use the original source.